List of Aveed drug patents

Aveed is owned by Endo Pharms Inc.

Aveed contains Testosterone Undecanoate.

Aveed has a total of 2 drug patents out of which 0 drug patents have expired.

Aveed was authorised for market use on 05 March, 2014.

Aveed is available in injectable;intramuscular dosage forms.

Aveed can be used as testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; primary hypogonadism (congenital or acquired); hypogonadotropic hypogonadism (congenital or acquired)..

The generics of Aveed are possible to be released after 08 May, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718640 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
Mar, 2027

(4 years from now)

US8338395 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
May, 2027

(4 years from now)

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 05 March, 2014

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypogonadism (congenital or acquired).

Dosage: INJECTABLE;INTRAMUSCULAR

How can I launch a generic of AVEED before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in